Tags

Type your tag names separated by a space and hit enter

The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial.
Diabet Med 1990; 7(4):319-23DM

Abstract

Twenty-two patients with distal diabetic polyneuropathy confirmed both clinically and by objective nerve function studies, completed a double-blind, placebo-controlled study to assess the effect of dietary supplementation with gamma-linolenic acid on their neuropathy. Patients received either 360 mg gamma-linolenic acid (12 patients) or indistinguishable placebo capsules (10 patients) for 6 months. All patients were assessed at the beginning and end of the study period by neuropathy symptom and sign scoring, motor and sensory nerve conduction studies, and thermal threshold measurements. When compared with the placebo group, patients on gamma-linolenic acid showed statistically significant improvement in neuropathy symptom scores (p less than 0.001), median nerve motor conduction velocity (p less than 0.01) and compound muscle action potential amplitude (p less than 0.01), peroneal nerve motor conduction velocity (p less than 0.05) and compound muscle action potential amplitude (p less than 0.05), median (p less than 0.01) and sural (p less than 0.001) sensory nerve action potential amplitude and ankle heat threshold (p less than 0.001) and cold threshold (p less than 0.01) values. gamma-Linolenic acid therapy might have a useful role in the prevention and treatment of distal diabetic polyneuropathy.

Authors+Show Affiliations

Glasgow University, Department of Neurology, UK.No affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article

Language

eng

PubMed ID

2159860

Citation

Jamal, G A., and H Carmichael. "The Effect of Gamma-linolenic Acid On Human Diabetic Peripheral Neuropathy: a Double-blind Placebo-controlled Trial." Diabetic Medicine : a Journal of the British Diabetic Association, vol. 7, no. 4, 1990, pp. 319-23.
Jamal GA, Carmichael H. The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabet Med. 1990;7(4):319-23.
Jamal, G. A., & Carmichael, H. (1990). The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. Diabetic Medicine : a Journal of the British Diabetic Association, 7(4), pp. 319-23.
Jamal GA, Carmichael H. The Effect of Gamma-linolenic Acid On Human Diabetic Peripheral Neuropathy: a Double-blind Placebo-controlled Trial. Diabet Med. 1990;7(4):319-23. PubMed PMID: 2159860.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of gamma-linolenic acid on human diabetic peripheral neuropathy: a double-blind placebo-controlled trial. AU - Jamal,G A, AU - Carmichael,H, PY - 1990/5/1/pubmed PY - 1990/5/1/medline PY - 1990/5/1/entrez SP - 319 EP - 23 JF - Diabetic medicine : a journal of the British Diabetic Association JO - Diabet. Med. VL - 7 IS - 4 N2 - Twenty-two patients with distal diabetic polyneuropathy confirmed both clinically and by objective nerve function studies, completed a double-blind, placebo-controlled study to assess the effect of dietary supplementation with gamma-linolenic acid on their neuropathy. Patients received either 360 mg gamma-linolenic acid (12 patients) or indistinguishable placebo capsules (10 patients) for 6 months. All patients were assessed at the beginning and end of the study period by neuropathy symptom and sign scoring, motor and sensory nerve conduction studies, and thermal threshold measurements. When compared with the placebo group, patients on gamma-linolenic acid showed statistically significant improvement in neuropathy symptom scores (p less than 0.001), median nerve motor conduction velocity (p less than 0.01) and compound muscle action potential amplitude (p less than 0.01), peroneal nerve motor conduction velocity (p less than 0.05) and compound muscle action potential amplitude (p less than 0.05), median (p less than 0.01) and sural (p less than 0.001) sensory nerve action potential amplitude and ankle heat threshold (p less than 0.001) and cold threshold (p less than 0.01) values. gamma-Linolenic acid therapy might have a useful role in the prevention and treatment of distal diabetic polyneuropathy. SN - 0742-3071 UR - https://www.unboundmedicine.com/medline/citation/2159860/The_effect_of_gamma_linolenic_acid_on_human_diabetic_peripheral_neuropathy:_a_double_blind_placebo_controlled_trial_ L2 - https://medlineplus.gov/diabeticnerveproblems.html DB - PRIME DP - Unbound Medicine ER -